Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UHI5

UPID:
LAT2_HUMAN

ALTERNATIVE NAMES:
L-type amino acid transporter 2; Solute carrier family 7 member 8

ALTERNATIVE UPACC:
Q9UHI5; B2R8Q4; B4DKT4; B4DTV6; D3DS46; F2Z2J4; Q86U05; Q9UKQ6; Q9UKQ7; Q9UKQ8; Q9Y445

BACKGROUND:
SLC7A8, known as L-type amino acid transporter 2, plays a pivotal role in amino acid homeostasis by mediating the exchange of extracellular essential amino acids with intracellular ones. It is involved in key physiological processes, including the reabsorption of neutral amino acids in the kidney, metal ion homeostasis, and the cellular activity of small molecular weight nitrosothiols. Additionally, SLC7A8 is responsible for the import of thyroid hormones and L-DOPA, highlighting its significance in various metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Solute carrier family 7 member 8 unveils promising avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.